Parabilis Medicines

📅 Upcoming

🕒 Recent(90d)

News

• Scribe’s early-stage IPO standout defies biotech’s derisking trend
  Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
  biospace · 11h ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 2d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 2d ago
• With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
  AI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.
  biospace · 8d ago
• 2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees
  Job postings increase and competition dips, according to BioSpace data.
  biospace · 13d ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 13d ago
• With $263M, LifeMine unearths a new drug for organ transplants
  Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
  biopharma_dive · 14d ago
• Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
  Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
  fiercebiotech · 14d ago
• ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
  A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking…
  fiercebiotech · 15d ago
• Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
  Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
  fiercebiotech · 20d ago